May saw several notable regulatory developments across the United States and Europe, reflecting continued advances in oncology, cardiovascular disease, rare diseases, and diabetes-related safety monitoring.

In the UK, NICE recommended Genmab’s Tivdak (tisotumab vedotin) for adults with recurrent or metastatic cervical cancer whose disease has progressed following systemic therapy. As the first antibody-drug conjugate approved in this setting, Tivdak offers a valuable alternative where treatment options have historically been limited.

In the United States, AstraZeneca received FDA approval for Baxfendy (baxdrostat), the first aldosterone synthase inhibitor approved for adults with uncontrolled hypertension. Clinical trial data demonstrated clinically meaningful reductions in blood pressure among patients whose condition remained inadequately controlled despite existing therapies.

The FDA also approved Taiho’s Inqovi (decitabine and cedazuridine) in combination with venetoclax for newly diagnosed acute myeloid leukaemia in older adults and patients unable to tolerate intensive chemotherapy. The approval introduces the first all-oral treatment option for this patient population, reducing the burden associated with frequent clinic visits.

Meanwhile, Satellite Bio received Rare Paediatric Disease designation from the FDA for SB-101, an investigational therapy for urea cycle disorders. The designation supports development of a first-in-class liver therapy designed to restore essential liver function in infants with severe early-onset disease.

On the pharmacovigilance front, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) identified several new safety signals requiring further evaluation, including potential associations involving benzodiazepines, semaglutide, dapagliflozin, tocilizumab, ixekizumab, and amoxicillin-containing medicines.

Advances in research and innovative therapies

Research and clinical development activity continued to demonstrate progress across infectious disease, chronic conditions, clinical trial optimisation, and antimicrobial resistance.

GSK reported positive phase 3 results for bepirovirsen, its investigational antisense oligonucleotide therapy for chronic hepatitis B. Trial results demonstrated functional cure rates significantly higher than current standards of care, with regulatory decisions anticipated later in 2026.

AMR Bio launched as a new clinical-stage biotechnology company focused on antimicrobial resistance, advancing XF-73 Nasal, a phase 3-ready antimicrobial gel designed to prevent surgical site infections. Clinical data demonstrated a 99.5% reduction in bacterial nasal carriage among surgical patients.

Patient communications agency Cuttsy+Cuttsy introduced “The Experience Gap”, a practical roadmap designed to improve participant engagement, support and retention throughout the clinical trial journey. The initiative addresses ongoing industry challenges around recruitment, diversity, and participant dropout.

Research partnerships also remained active. Regeneron entered a strategic collaboration with Parabilis Medicines to develop therapeutics using Parabilis’ Helicon peptide platform, including novel antibody-helicon conjugates targeting historically difficult-to-drug intracellular proteins.

GSK also expanded its relationship with Protas through a new three-year agreement aimed at improving the quality, efficiency, and accessibility of late-stage clinical trials across multiple therapeutic areas.

Additionally, Boehringer Ingelheim signed a global licensing agreement with Immunitas Therapeutics to advance a preclinical antibody programme targeting chronic inflammatory and autoimmune diseases, strengthening its growing immunology pipeline.

Industry partnerships, investments and acquisitions

Strategic collaborations, acquisitions, and infrastructure investments continued to shape the competitive landscape and support future growth.

Angelini Pharma announced plans to acquire Catalyst Pharmaceuticals in a $4.1 billion transaction, expanding its presence in rare diseases and neurological therapies, particularly in the United States.

Eli Lilly continued its aggressive expansion strategy through several transactions. The company agreed to acquire Curevo for up to $1.5 billion, strengthening its infectious disease portfolio with a next-generation shingles vaccine candidate. Lilly also announced acquisitions of LimmaTech Biologics and Vaccine Company in deals worth up to $2.33 billion combined, reinforcing its long-term focus on infectious disease prevention and vaccine innovation.

In dermatology, LEO Pharma agreed to acquire Replay, a gene therapy company focused on rare genetic skin diseases. The acquisition adds an HSV-based gene therapy platform to LEO’s growing dermatology pipeline and supports future development in rare skin disorders.

Beyond acquisitions, Novartis broke ground on a new radioligand therapy manufacturing facility in Texas as part of its broader $23 billion US investment programme. The facility will expand production capacity for personalised cancer therapies and strengthen domestic manufacturing capabilities.

Eli Lilly also announced an additional $4.5 billion investment in its Indiana manufacturing network, bringing total US capital expansion commitments since 2020 to more than $50 billion and supporting production of obesity, diabetes, and genetic medicines.

Healthcare initiatives and patient-centred innovation

Healthcare organisations continued to invest in awareness, access, digital transformation, and patient engagement.

LEO Pharma and Allergy UK launched the “Don’t Ignore” campaign to improve awareness of chronic hand eczema and encourage earlier diagnosis and treatment. The campaign aims to help patients recognise symptoms sooner and seek medical advice before the condition significantly impacts daily life.

Bristol Myers Squibb announced a strategic agreement with Anthropic to deploy advanced AI capabilities across research, development, manufacturing, and commercial functions. The initiative marks a broader move toward agentic AI systems capable of supporting complex workflows and accelerating decision-making.

Global health partnerships also gained momentum. Eli Lilly and UNICEF launched a six-year collaboration aimed at improving prevention and care for non-communicable diseases among children and adolescents across 21 low- and middle-income countries. The programme aims to reach more than 30 million children and caregivers through strengthened primary healthcare systems.

Meanwhile, UCB presented new data highlighting the broader impact of epilepsy on patients and caregivers, including the effects of sleep disruption, prolonged seizures, and healthcare resource utilisation.

Expanded access programmes also remained a focus area, with Uniphar publishing guidance on improving experiences for healthcare professionals and patients through streamlined enrolment processes, digital support tools, and patient-centred programme design.

Market access, patient engagement and healthcare communications

Several thought leadership initiatives highlighted the growing importance of patient engagement, healthcare communications, and market access strategy.

Mednet continued to promote its Making Health Whole™ philosophy through a series of articles exploring how emotional, behavioural, and practical factors influence patient engagement and long-term health outcomes. The articles emphasised that clinical innovation alone is insufficient if healthcare systems fail to support patients throughout the realities of daily life.

ValueBase published new perspectives on pharmaceutical launch performance and market access, highlighting the importance of sub-national implementation and local healthcare system dynamics. The company argued that national reimbursement decisions alone do not guarantee patient access and called for greater visibility into local adoption and prescribing patterns.

Patient engagement measurement also remained a key topic, with industry discussions increasingly focused on evaluating the influence of patient insights on organisational decision-making rather than relying solely on activity-based metrics.

Healthcare leadership and mentorship were also explored through new thought leadership content emphasising the role of listening, psychological safety, and human connection in improving both professional development and patient care.

Looking ahead

May’s developments demonstrate a life sciences sector increasingly focused on delivering innovation alongside accessibility, patient engagement, and real-world impact.

From first-in-class cardiovascular therapies and promising hepatitis B treatments to major investments in manufacturing, AI-enabled healthcare transformation, and strategic acquisitions across infectious disease, neurology, and dermatology, organisations continue to invest heavily in addressing unmet medical needs.

As regulatory agencies, healthcare providers, pharmaceutical companies, and patient organisations work together to accelerate innovation and improve outcomes, the importance of patient-centred care, digital transformation, and healthcare system readiness continues to grow.

Essjay Solutions will continue to monitor these developments and provide insights into the latest regulatory, clinical, research, healthcare, and market access trends.